Gossamer Bio is a San Diego-based company focused on the discovery and development of novel and differentiated therapeutic products, to address high unmet needs amongst various targeted patient populations. Founded by the former Receptos executive team, Gossamer Bio’s strategy will be to leverage an asset-rich in-licensing environment, with a focus on areas of high unmet need, utilizing a team with a strong track record of execution in immunology, inflammation, fibrosis and oncology.
Senti Biosciences is a clinical-stage biotechnology company based in South San Francisco, California, focused on developing innovative gene and cell therapies using its proprietary synthetic biology platform. Founded in 2016, the company aims to address complex diseases through advanced therapeutic solutions. Senti's technology includes engineered allogeneic chimeric antigen receptor natural killer (CAR-NK) cells, which are designed to target and eliminate cancer cells while minimizing damage to healthy tissue. Among its product candidates are SENTI-202, a Logic Gated CAR-NK cell therapy intended for cancer treatment, and SENTI-301A, which targets hepatocellular carcinoma. Senti Biosciences operates as a resident company at Johnson & Johnson Innovation's JLABS in South San Francisco, collaborating with experts in synthetic biology and computation to advance its therapeutic developments.
Celcuity Inc. is a clinical-stage biotechnology company based in Minneapolis, Minnesota, focused on advancing cancer care through innovative diagnostic and therapeutic solutions. The company's CELsignia diagnostic platform analyzes living tumor cells from patients to identify the specific abnormal cellular processes driving their cancer, enabling personalized treatment options. Celcuity is developing the CELsignia HSF test to diagnose new sub-types of HER2-negative breast cancer, as well as the CELsignia MP test to identify multiple cancer sub-types across various types, including breast, lung, colon, ovarian, kidney, and bladder cancers. In addition to its diagnostic efforts, Celcuity is advancing a lead therapeutic candidate, gedatolisib, a potent pan-PI3K and mTOR inhibitor, which is currently being evaluated in a Phase 3 clinical trial for patients with HR+/HER2- advanced breast cancer. Founded in 2011, Celcuity aims to transform the treatment landscape for patients with cancer by providing targeted therapies tailored to their unique disease profiles.
Splice Bio is a gene therapy company based on technology developed in the Muir Lab at Princeton University. The company is developing novel gene therapies based on its proprietary intein platform technology to treat patients that suffer from incurable genetic diseases. The company’s platform has the potential to address two existing limitations of adeno-associated viruses (AAVs), both by increasing the size of the cargo gene that can be delivered and by expanding the range of tissues that can be targeted.
Aquabyte, Inc. specializes in developing advanced monitoring systems for the aquaculture industry, focusing on enhancing fish farming efficiency through machine learning and computer vision technologies. Founded in 2017 and headquartered in San Francisco with an additional office in Bergen, Norway, Aquabyte's innovative solutions include a smart camera system that facilitates real-time sea lice counting, biomass estimation, appetite detection, and feed optimization. By providing a comprehensive web dashboard for continuous monitoring, Aquabyte enables fish farms to reduce operational costs and minimize environmental impacts, ultimately contributing to a more sustainable and profitable aquaculture sector. The company's commitment to leveraging technology aims to address challenges in food production, making a significant impact on the industry's growth and efficiency.
Korro Bio Inc. specializes in the development of nucleic acid-based therapeutics aimed at targeting specific sequences in genetic code, with a focus on treating rare diseases. Founded in 2018 and located in Cambridge, Massachusetts, the company utilizes a proprietary platform that enables efficient and selective RNA editing by leveraging natural processes found in multi-cellular organisms. This innovative approach allows Korro Bio to edit messenger RNA and recode specific codons, facilitating targeted modifications in protein structure and function across various tissues.
Sorriso Pharmaceuticals is a biotechnology company based in San Diego, California, founded in 2020. The company focuses on developing disease-modifying antibodies aimed at treating inflammatory diseases such as Crohn's disease and ulcerative colitis. Sorriso's innovative platform produces potent antibodies that can be delivered orally, ensuring they remain effective throughout the intestinal system. This approach aims to provide clinical benefits comparable to traditional injectable antibody therapeutics, thereby alleviating the treatment burden for patients who typically rely on injections for their care. By advancing its pipeline of oral therapies, Sorriso Pharmaceuticals seeks to improve patient outcomes and enhance the management of inflammatory diseases.
Tune Therapeutics is focused on developing innovative cell and gene therapies that utilize epigenetic programming to address serious diseases. By harnessing the potential of the epigenome, the company aims to create new therapeutic pathways that modify biological functions without changing the underlying DNA sequence. This approach seeks to provide effective treatments for complex and widespread diseases, positioning Tune Therapeutics at the forefront of advancements in epigenetic medicine.
AviadoBio mission is to transform the lives of people living with neurodegenerative disorders by developing and delivering transformative gene therapies for diseases including frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). The Company’s technology is based on pioneering research from King’s College London and the UK Dementia Research Institute.
Regulus Therapeutics Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery and development of therapies that target microRNAs to address various diseases. Its primary product candidates include RG-012, an anti-miR targeting miR-21, currently in Phase II clinical trials for Alport syndrome, a severe kidney condition, and RGLS4326, an anti-miR aimed at miR-17, which is undergoing Phase Ib clinical trials for autosomal dominant polycystic kidney disease. In addition to these lead candidates, Regulus is cultivating a preclinical pipeline that includes RGLS5579, targeting miR-10b, as well as programs focused on Hepatitis B and Non-Alcoholic Steatohepatitis. Founded in 2007, Regulus Therapeutics is headquartered in San Diego, California.
Recludix pharma is a developing platform to discover potent and selective inhibitors of challenging protein targets. The platform approach integrates custom generated DNA-encoded libraries, massively parallel determination of structure-activity relationships, and a proprietary screening tool to ensure selectivity.
858 Therapeutics
Series A in 2021
858 Therapeutics is a stealth company specializing in the area of healthcare services, pharmaceutical, and biotechnology. The company was founded in 2019 and is headquartered in San Diego, California, USA.
Shape Therapeutics, Inc. is a biotechnology company based in Seattle, Washington, focused on RNA-editing gene therapy for various medical conditions, including neurodegenerative disorders, oncology, metabolic diseases, and rare genetic diseases. Founded in 2018, the company has developed RNAfix technology, which utilizes the natural cellular machinery of the human body to edit RNA. This approach significantly reduces the risks of immunogenicity, cellular toxicity, and off-target DNA editing that are often associated with traditional gene-editing methods, such as CRISPR. Shape Therapeutics aims to create next-generation gene therapies that provide effective and safer treatment options for patients with challenging medical conditions.
Shape Therapeutics, Inc. is a biotechnology company based in Seattle, Washington, focused on RNA-editing gene therapy for various medical conditions, including neurodegenerative disorders, oncology, metabolic diseases, and rare genetic diseases. Founded in 2018, the company has developed RNAfix technology, which utilizes the natural cellular machinery of the human body to edit RNA. This approach significantly reduces the risks of immunogenicity, cellular toxicity, and off-target DNA editing that are often associated with traditional gene-editing methods, such as CRISPR. Shape Therapeutics aims to create next-generation gene therapies that provide effective and safer treatment options for patients with challenging medical conditions.
Stablix Therapeutics is a biotechnology company pioneering the field of Targeted Protein Stabilization (TPS). The company’s resorted platform generates heterobifunctional small molecules (RESTORACS) that recruit deubiquitinase enzymes to remove ubiquitin from targeted proteins and consequently stabilize or increase target protein levels and activity. Stablix initially is leveraging the platform to develop programs to treat rare diseases, cancer, and immunological disorders.
Affinia Therapeutics Inc. is a biotechnology company focused on developing gene therapies for various diseases, particularly those affecting muscle and the central nervous system (CNS). Founded in 2019 and based in Waltham, Massachusetts, the company specializes in creating rationally designed adeno-associated virus (AAV) vectors. By integrating synthetic and systems biology with high-throughput screening and advanced resolution techniques, Affinia Therapeutics aims to address significant unmet medical needs. The company’s innovative approach allows for the development of novel gene therapies with enhanced properties, targeting the treatment of devastating diseases and improving the lives of affected individuals.
Code Biotherapeutics
Seed Round in 2021
Code Biotherapeutics is a next-generation gene therapy company pioneering the development of targeted non-viral gene therapies to treat serious and life-threatening genetic diseases. Code Bio leverages its novel multivalent synthetic DNA delivery platform, 3DNA, which has been engineered to overcome many of the challenges inherent with viral-based gene therapies such as immunogenicity, size and delivery limitations, re-dosability, and manufacturing complexity. The Company is advancing an internal pipeline focused on select rare disease programs as well as establishing partnerships to take forward programs in both rare and prevalent diseases.
Monte Rosa Therapeutics is a biotechnology company based in Basel, Switzerland, that specializes in developing innovative cancer therapeutics through the modulation of protein degradation pathways. The company focuses on molecular glue degraders (MGDs), a class of small molecule drugs that utilize the body's natural mechanisms for protein degradation to selectively target and degrade proteins relevant to cancer treatment. Monte Rosa employs its QuEEN platform, which integrates artificial intelligence and proprietary experimental tools, to identify and develop target proteins for degradation. With a library of over 50,000 MGD molecules, its leading product candidate, MRT-2359, specifically targets the translation termination factor protein GSPT1, showing potential for treating MYC-driven tumors. The company is committed to advancing its pipeline of novel therapeutics to address unmet medical needs in oncology.
Sagimet Biosciences is a biotechnology company that focuses on developing novel therapeutics to treat important diseases such as liver disease NASH and specific cancers, with a focus on targeting dysfunctional metabolic pathways. It was founded in 2007 and headquartered in San Mateo, California.
Personal Genome Diagnostics develops a patient-specific analysis of the cancer genome by using advanced tools and technologies. They were the first to sequence and analyze whole human cancer exomes and subsequently identified many alterations responsible for the development of cancer. They have described the principles underlying the genetic basis of human cancer and have developed novel technologies for non-invasive “liquid biopsy” approaches in cancer. Through PGDx, our founders bring their proprietary methods and expertise to research teams worldwide. The services help oncologists and translational scientists sequence and analyze cancer genomes and identify mutations to characterize aspects of the disease. Their expertise in genome analysis ranges from sample preparation and sequencing to data interpretation and analysis. They specialize in high-throughput next-generation sequencing and proprietary algorithms to identify alterations in complex cancer genomes and have developed novel technologies for non-invasive “liquid biopsy” approaches in cancer. Personal Genome Diagnostics was founded in 2010 and is based in Baltimore, Maryland, United States.
New Wave Foods, Inc. specializes in producing and selling plant-based seafood products, focusing primarily on sustainable shrimp alternatives. Founded in 2015 and headquartered in San Francisco, California, the company offers a variety of items, including sautéed, grilled, breaded, and fried shrimp, as well as shrimp tacos and salads. Its products are made from sustainably sourced seaweed and soy protein, enriched with natural flavors and essential amino acids, providing a healthy, low-calorie, and zero-cholesterol option for consumers. Targeting the culinary market in the United States, New Wave Foods aims to preserve and enrich seafood traditions through its innovative plant-based offerings.
Senti Biosciences is a clinical-stage biotechnology company based in South San Francisco, California, focused on developing innovative gene and cell therapies using its proprietary synthetic biology platform. Founded in 2016, the company aims to address complex diseases through advanced therapeutic solutions. Senti's technology includes engineered allogeneic chimeric antigen receptor natural killer (CAR-NK) cells, which are designed to target and eliminate cancer cells while minimizing damage to healthy tissue. Among its product candidates are SENTI-202, a Logic Gated CAR-NK cell therapy intended for cancer treatment, and SENTI-301A, which targets hepatocellular carcinoma. Senti Biosciences operates as a resident company at Johnson & Johnson Innovation's JLABS in South San Francisco, collaborating with experts in synthetic biology and computation to advance its therapeutic developments.
Reneo Pharmaceuticals develops therapies for patients with rare genetic mitochondrial diseases, which impact cellular metabolism and energy production. Founded in 2014 and based in San Diego, California, the company is focused on creating treatments that enhance mitochondrial function, thereby improving muscle health and overall quality of life for affected individuals. Its lead product candidate, REN001, is an oral medication designed to modulate genes essential for energy metabolism and the production of adenosine triphosphate (ATP), the primary energy source for cellular processes. By addressing the underlying metabolic deficiencies in these patients, Reneo aims to prevent muscle injury, weakness, and wasting, ultimately enhancing daily functioning for those with these orphan diseases.
Resilience is a biopharmaceutical manufacturing and technology company based in La Jolla, California, established in 2020. It aims to enhance access to complex medicines and safeguard biopharmaceutical supply chains. The company specializes in end-to-end manufacturing and development solutions across various therapeutic modalities, including cell and gene therapies, viral vectors, vaccines, and proteins. Resilience provides customized manufacturing capabilities that cater to the diverse needs of biopharmaceuticals at all stages of the drug development process, from pre-clinical development to commercial supply. With a focus on developing new manufacturing technologies, Resilience ensures high-quality and regulatory-compliant processes for complex and novel medicines.
Monte Rosa Therapeutics is a biotechnology company based in Basel, Switzerland, that specializes in developing innovative cancer therapeutics through the modulation of protein degradation pathways. The company focuses on molecular glue degraders (MGDs), a class of small molecule drugs that utilize the body's natural mechanisms for protein degradation to selectively target and degrade proteins relevant to cancer treatment. Monte Rosa employs its QuEEN platform, which integrates artificial intelligence and proprietary experimental tools, to identify and develop target proteins for degradation. With a library of over 50,000 MGD molecules, its leading product candidate, MRT-2359, specifically targets the translation termination factor protein GSPT1, showing potential for treating MYC-driven tumors. The company is committed to advancing its pipeline of novel therapeutics to address unmet medical needs in oncology.
Polyneuron Pharmaceuticals AG is focused on developing innovative therapeutics for the treatment of antibody-mediated autoimmune disorders. The company is working on several drug candidates, including PN-1007 for anti-MAG neuropathy, PN-1018 for multifocal motor neuropathy, and PN-032 and PN-056 for ABO-incompatible transplantation. Polyneuron utilizes a platform technology called Antibody-Catch, which is based on biodegradable glycopolymers. This technology selectively targets and eliminates pathological autoantibodies while preserving the integrity of the rest of the immune system. Founded in 2014 and headquartered in Basel, Switzerland, Polyneuron aims to provide safe and effective treatment options for patients suffering from autoimmune diseases affecting the peripheral nervous system.
Korro Bio Inc. specializes in the development of nucleic acid-based therapeutics aimed at targeting specific sequences in genetic code, with a focus on treating rare diseases. Founded in 2018 and located in Cambridge, Massachusetts, the company utilizes a proprietary platform that enables efficient and selective RNA editing by leveraging natural processes found in multi-cellular organisms. This innovative approach allows Korro Bio to edit messenger RNA and recode specific codons, facilitating targeted modifications in protein structure and function across various tissues.
MBX Biosciences, Inc. is a biotechnology company based in Carmel, Indiana, specializing in the development of therapeutics for rare endocrine disorders. Founded in 2018, the company aims to address unmet medical needs by discovering and commercializing innovative treatments for endocrine diseases that affect hormonal regulation in the body. MBX Biosciences focuses on creating first-in-class therapies, particularly utilizing peptides to target rare genetic conditions related to glandular hormone secretion.
Monte Rosa Therapeutics is a biotechnology company based in Basel, Switzerland, that specializes in developing innovative cancer therapeutics through the modulation of protein degradation pathways. The company focuses on molecular glue degraders (MGDs), a class of small molecule drugs that utilize the body's natural mechanisms for protein degradation to selectively target and degrade proteins relevant to cancer treatment. Monte Rosa employs its QuEEN platform, which integrates artificial intelligence and proprietary experimental tools, to identify and develop target proteins for degradation. With a library of over 50,000 MGD molecules, its leading product candidate, MRT-2359, specifically targets the translation termination factor protein GSPT1, showing potential for treating MYC-driven tumors. The company is committed to advancing its pipeline of novel therapeutics to address unmet medical needs in oncology.
Affinia Therapeutics Inc. is a biotechnology company focused on developing gene therapies for various diseases, particularly those affecting muscle and the central nervous system (CNS). Founded in 2019 and based in Waltham, Massachusetts, the company specializes in creating rationally designed adeno-associated virus (AAV) vectors. By integrating synthetic and systems biology with high-throughput screening and advanced resolution techniques, Affinia Therapeutics aims to address significant unmet medical needs. The company’s innovative approach allows for the development of novel gene therapies with enhanced properties, targeting the treatment of devastating diseases and improving the lives of affected individuals.
Akouos, Inc. is a biotechnology company that specializes in developing gene therapies aimed at restoring and preserving hearing for individuals with hearing loss. The company utilizes a proprietary platform that includes a library of adeno-associated viral vectors and innovative delivery methods. Its lead product candidate, AK-OTOF, targets hearing loss caused by mutations in the OTOF gene. Akouos is committed to addressing various forms of sensorineural hearing loss, which can result from genetic mutations, ototoxic drug exposure, and aging. Founded in 2016 and headquartered in Boston, Massachusetts, Akouos has formed strategic partnerships with organizations such as Massachusetts Eye and Ear and Lonza, Inc. to enhance its research and development efforts.
Inventiva S.A. is a biopharmaceutical company based in Daix, France, specializing in the development of oral small molecule therapies targeting significant unmet medical needs in fibrosis, lysosomal storage disorders, and oncology. The company's lead candidate, Lanifibranor, is currently in Phase IIb clinical trials for the treatment of nonalcoholic steatohepatitis. Additionally, Inventiva is advancing Odiparcil, in Phase IIa trials for mucopolysaccharidosis type VI, and has several preclinical programs, including potential treatments for malignant mesothelioma and lung cancer. The company's research and development efforts are supported by a proprietary library of molecules and a team experienced in targeting nuclear receptors and transcription factors. Inventiva has established partnerships with prominent organizations, including the Institut Curie for oncology research and AbbVie for autoimmune disease treatments. Founded in 2011, the company continues to focus on innovative solutions for complex medical conditions.
Geron Corporation is a late-stage clinical biopharmaceutical company based in Menlo Park, California, specializing in the development and commercialization of therapeutics for hematologic myeloid malignancies. The company's primary focus is on imetelstat, a first-in-class telomerase inhibitor currently undergoing Phase 2/3 clinical trials. Imetelstat aims to inhibit the uncontrolled growth of malignant progenitor cells in these cancers, which helps reduce the production of dysfunctional blood cells and facilitates the recovery of normal blood cell production. Founded in 1990, Geron is dedicated to advancing innovative treatments for patients with serious blood disorders.
At Affimed, they are committed to improving outcomes for patients with cancer. Their scientific team has been devoted to unlocking the power of the innate immune system for nearly two decades to provide a unqiue approach to fighting cancer. With their unparalleled expertise in innate immunity and innate cell engager-based medicines, they aim to overcome the limitations and challenges faced by current immuno-oncology (I-O) therapies.
ERYTECH Pharma S.A. is a clinical-stage biopharmaceutical company based in Lyon, France, founded in 2004. The company specializes in the development of red blood cell-based therapeutics aimed at treating cancer and orphan diseases. Its lead product candidate, eryaspase, is currently undergoing Phase III clinical trials for second-line pancreatic cancer and Phase II trials for triple-negative breast cancer. Additionally, ERYTECH is developing erymethionase, a preclinical candidate targeting methionine-dependent cancers, which consists of methionine-gamma-lyase encapsulated in red blood cells. The company collaborates with research institutions such as the Fox Chase Cancer Center and Queen’s University of Canada to enhance the preclinical development of its products for conditions like homocystinuria and arginase-1 deficiency, respectively. Through its innovative approach to encapsulating therapeutic molecules, ERYTECH Pharma aims to improve the efficacy and safety of its treatments.
ChromaCode, Inc. is a molecular diagnostics company based in Carlsbad, California, that specializes in developing innovative testing solutions for infectious diseases, cancer, and non-invasive prenatal testing (NIPT) using proprietary technology derived from Caltech. The company enhances the performance of quantitative polymerase chain reaction (qPCR) instruments, achieving a five-fold increase in multiplexing capabilities while maintaining cost-effectiveness. ChromaCode employs advanced bioinformatics techniques and patented mathematical methods to improve signal processing, enabling laboratories to conduct comprehensive testing of multiple targets in a single sample. Additionally, the company offers products such as the HDPCR Tick-Borne Pathogen Panel, which detects various tick-borne pathogens through a multiplex polymerase chain reaction test. Founded in 2012, ChromaCode draws expertise from professionals with backgrounds in leading organizations such as Illumina and Google[x].
Black Diamond Therapeutics is a precision oncology medicine company focused on discovering and developing small molecule, tumor-agnostic therapies. The company's lead product candidate, BDTX-189, is designed to inhibit specific mutations in ErbB kinases, including the epidermal growth factor receptor. Additionally, Black Diamond is advancing a pipeline of allosteric-EGFR mutation inhibitors and other early-stage programs targeting allosteric mutations in kinases associated with cancer and rare genetic diseases. The company employs a technology platform known as Mutation-Allostery-Pharmacology, which aims to address undrugged mutations in patients with genetically defined cancers. Founded in 2014 and based in Cambridge, Massachusetts, Black Diamond Therapeutics was previously known as ASET Therapeutics until its rebranding in 2018.
Shape Therapeutics, Inc. is a biotechnology company based in Seattle, Washington, focused on RNA-editing gene therapy for various medical conditions, including neurodegenerative disorders, oncology, metabolic diseases, and rare genetic diseases. Founded in 2018, the company has developed RNAfix technology, which utilizes the natural cellular machinery of the human body to edit RNA. This approach significantly reduces the risks of immunogenicity, cellular toxicity, and off-target DNA editing that are often associated with traditional gene-editing methods, such as CRISPR. Shape Therapeutics aims to create next-generation gene therapies that provide effective and safer treatment options for patients with challenging medical conditions.
Shape Therapeutics, Inc. is a biotechnology company based in Seattle, Washington, focused on RNA-editing gene therapy for various medical conditions, including neurodegenerative disorders, oncology, metabolic diseases, and rare genetic diseases. Founded in 2018, the company has developed RNAfix technology, which utilizes the natural cellular machinery of the human body to edit RNA. This approach significantly reduces the risks of immunogenicity, cellular toxicity, and off-target DNA editing that are often associated with traditional gene-editing methods, such as CRISPR. Shape Therapeutics aims to create next-generation gene therapies that provide effective and safer treatment options for patients with challenging medical conditions.
Inventiva S.A. is a biopharmaceutical company based in Daix, France, specializing in the development of oral small molecule therapies targeting significant unmet medical needs in fibrosis, lysosomal storage disorders, and oncology. The company's lead candidate, Lanifibranor, is currently in Phase IIb clinical trials for the treatment of nonalcoholic steatohepatitis. Additionally, Inventiva is advancing Odiparcil, in Phase IIa trials for mucopolysaccharidosis type VI, and has several preclinical programs, including potential treatments for malignant mesothelioma and lung cancer. The company's research and development efforts are supported by a proprietary library of molecules and a team experienced in targeting nuclear receptors and transcription factors. Inventiva has established partnerships with prominent organizations, including the Institut Curie for oncology research and AbbVie for autoimmune disease treatments. Founded in 2011, the company continues to focus on innovative solutions for complex medical conditions.
Nkarta Therapeutics is a biopharmaceutical company focused on developing engineered natural killer (NK) cell therapies for cancer treatment. Founded in 2015 and headquartered in South San Francisco, California, Nkarta aims to enhance the efficacy and tolerability of cell therapies, addressing both hematologic and solid tumor malignancies. The company's approach utilizes chimeric antigen receptors on NK cells, enabling them to recognize and attack tumor cells more effectively. Nkarta's lead product candidates include NKX101, designed to harness innate NK cell biology for cancer detection and destruction, and NKX019, targeting the CD19 antigen to treat various B cell malignancies. By leveraging its NK expansion platform and proprietary cell engineering technologies, Nkarta seeks to provide a more potent and accessible treatment option, capitalizing on the natural ability of NK cells to identify and eliminate abnormal cells while minimizing side effects typically associated with other therapies.
Sagimet Biosciences is a biotechnology company that focuses on developing novel therapeutics to treat important diseases such as liver disease NASH and specific cancers, with a focus on targeting dysfunctional metabolic pathways. It was founded in 2007 and headquartered in San Mateo, California.
Aquabyte, Inc. specializes in developing advanced monitoring systems for the aquaculture industry, focusing on enhancing fish farming efficiency through machine learning and computer vision technologies. Founded in 2017 and headquartered in San Francisco with an additional office in Bergen, Norway, Aquabyte's innovative solutions include a smart camera system that facilitates real-time sea lice counting, biomass estimation, appetite detection, and feed optimization. By providing a comprehensive web dashboard for continuous monitoring, Aquabyte enables fish farms to reduce operational costs and minimize environmental impacts, ultimately contributing to a more sustainable and profitable aquaculture sector. The company's commitment to leveraging technology aims to address challenges in food production, making a significant impact on the industry's growth and efficiency.
Reneo Pharmaceuticals develops therapies for patients with rare genetic mitochondrial diseases, which impact cellular metabolism and energy production. Founded in 2014 and based in San Diego, California, the company is focused on creating treatments that enhance mitochondrial function, thereby improving muscle health and overall quality of life for affected individuals. Its lead product candidate, REN001, is an oral medication designed to modulate genes essential for energy metabolism and the production of adenosine triphosphate (ATP), the primary energy source for cellular processes. By addressing the underlying metabolic deficiencies in these patients, Reneo aims to prevent muscle injury, weakness, and wasting, ultimately enhancing daily functioning for those with these orphan diseases.
Polyneuron Pharmaceuticals AG is focused on developing innovative therapeutics for the treatment of antibody-mediated autoimmune disorders. The company is working on several drug candidates, including PN-1007 for anti-MAG neuropathy, PN-1018 for multifocal motor neuropathy, and PN-032 and PN-056 for ABO-incompatible transplantation. Polyneuron utilizes a platform technology called Antibody-Catch, which is based on biodegradable glycopolymers. This technology selectively targets and eliminates pathological autoantibodies while preserving the integrity of the rest of the immune system. Founded in 2014 and headquartered in Basel, Switzerland, Polyneuron aims to provide safe and effective treatment options for patients suffering from autoimmune diseases affecting the peripheral nervous system.
Black Diamond Therapeutics is a precision oncology medicine company focused on discovering and developing small molecule, tumor-agnostic therapies. The company's lead product candidate, BDTX-189, is designed to inhibit specific mutations in ErbB kinases, including the epidermal growth factor receptor. Additionally, Black Diamond is advancing a pipeline of allosteric-EGFR mutation inhibitors and other early-stage programs targeting allosteric mutations in kinases associated with cancer and rare genetic diseases. The company employs a technology platform known as Mutation-Allostery-Pharmacology, which aims to address undrugged mutations in patients with genetically defined cancers. Founded in 2014 and based in Cambridge, Massachusetts, Black Diamond Therapeutics was previously known as ASET Therapeutics until its rebranding in 2018.
Tiburio Therapeutics is a developer of drug compounds intended to treat tumors and endocrine diseases.The company's compounds aid in the treatment of non-functioning pituitary adenoma using a dopamine-somatostatin chimeric molecule that has the potential to shrink or halt tumor growth, providing patients with effective treatment for rare neuroendocrine tumors and endocrine diseases.
Xenon Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company based in Burnaby, Canada, focused on developing innovative therapeutics for neurological disorders. The company's clinical pipeline includes several product candidates targeting epilepsy, such as XEN496 and XEN1101, both Kv7 potassium channel modulators currently in Phase II trials, and XEN901, a selective Nav1.6 sodium channel inhibitor in Phase I trials. Additionally, XEN007, a central nervous system-acting calcium channel modulator, is also in Phase I trials. Xenon utilizes a proprietary discovery platform, known as Extreme Genetics, to identify genetic insights from families with severe phenotypes, enabling the development of novel medicines for both orphan and more common diseases. The company has established a collaboration with Neurocrine Biosciences to advance first-in-class treatments for epilepsy, highlighting its commitment to addressing unmet medical needs in the field of neurology.
Qpex Biopharma is a San Diego-based biopharmaceutical company founded in 2018, focused on developing innovative therapies to address the growing challenge of antimicrobial resistance. The company specializes in creating a pipeline of antibiotic drugs aimed at treating infectious diseases in both inpatient and outpatient settings. With a strong emphasis on the discovery, development, and regulatory approval of anti-infective medicines, Qpex Biopharma leverages its expertise and experience in collaboration with public and private partnerships to meet critical medical needs. The company's mission is to provide effective solutions for healthcare professionals facing the complexities of resistant infections, thereby enhancing treatment options for patients.
PhaseBio Pharmaceuticals is a clinical-stage biopharmaceutical company based in Malvern, Pennsylvania, focused on developing innovative therapies for cardiopulmonary diseases. Its lead product candidate, PB2452, is a reversal agent for the antiplatelet drug ticagrelor and is currently undergoing Phase III clinical trials for patients experiencing uncontrolled bleeding or requiring urgent surgery. The company is also advancing PB1046, a fusion protein aimed at treating pulmonary arterial hypertension, which is in Phase IIb clinical trials. Additionally, PhaseBio is developing PB6440, an oral agent intended for the treatment of resistant hypertension. Founded in 2002, the company leverages proprietary recombinant biopolymers to enhance the stability and efficacy of its drug candidates.
Akouos, Inc. is a biotechnology company that specializes in developing gene therapies aimed at restoring and preserving hearing for individuals with hearing loss. The company utilizes a proprietary platform that includes a library of adeno-associated viral vectors and innovative delivery methods. Its lead product candidate, AK-OTOF, targets hearing loss caused by mutations in the OTOF gene. Akouos is committed to addressing various forms of sensorineural hearing loss, which can result from genetic mutations, ototoxic drug exposure, and aging. Founded in 2016 and headquartered in Boston, Massachusetts, Akouos has formed strategic partnerships with organizations such as Massachusetts Eye and Ear and Lonza, Inc. to enhance its research and development efforts.
Catalog Technologies Inc. is a Boston-based company that specializes in a DNA-based platform designed for digital data storage and computation. Founded in 2016, Catalog's innovative platform encodes digital information into DNA, providing a new approach to long-term data archiving. This method not only enhances data storage capacity but also offers a cost-effective solution for managing vast amounts of information. By integrating advanced synthetic biology technologies, Catalog aims to revolutionize the way digital data is archived and processed, making DNA a viable medium for future data storage needs.
WaterBit’s automated irrigation solution enables control of local irrigation taking into account growth stage and soil conditions at a level of granularity and accuracy that is not possible with other current methods. WaterBit translates technology into tangible value for growers to improve yields, ensure crop quality, optimize water usage and implement labor saving strategies.
MEI Pharma, Inc. (Nasdaq: MEIP) is a San Diego-based oncology company focused on the clinical development of novel therapies for cancer. The Company’s clinical development pipeline includes lead drug candidate Pracinostat, a potential best-in-class, oral histone deacetylase (HDAC) inhibitor. Pracinostat has been tested in more than 150 patients in multiple Phase I and exploratory Phase II clinical trials, including advanced hematologic malignancies such as myelodysplastic syndrome, acute myeloid leukemia and myelofibrosis. The Company expects to initiate a randomized Phase II trial of Pracinostat in combination with standard-of-care in at least one hematologic malignancy toward the middle of 2013. In addition, MEI Pharma is developing two drug candidates derived from its isoflavone-based technology platform, ME-143 and ME-344. Results from a Phase I trial of intravenous ME-143 in heavily treated patients with solid refractory tumors were presented at the American Society of Clinical Oncology Annual Meeting in June 2012. A Phase I clinical trial of intravenous ME-344 in patients with solid refractory tumors is ongoing.
Senti Biosciences is a clinical-stage biotechnology company based in South San Francisco, California, focused on developing innovative gene and cell therapies using its proprietary synthetic biology platform. Founded in 2016, the company aims to address complex diseases through advanced therapeutic solutions. Senti's technology includes engineered allogeneic chimeric antigen receptor natural killer (CAR-NK) cells, which are designed to target and eliminate cancer cells while minimizing damage to healthy tissue. Among its product candidates are SENTI-202, a Logic Gated CAR-NK cell therapy intended for cancer treatment, and SENTI-301A, which targets hepatocellular carcinoma. Senti Biosciences operates as a resident company at Johnson & Johnson Innovation's JLABS in South San Francisco, collaborating with experts in synthetic biology and computation to advance its therapeutic developments.
Liquidia Technologies is a late-stage clinical biopharmaceutical company based in Morrisville, North Carolina, that specializes in the development and commercialization of human therapeutics. The company utilizes its proprietary PRINT technology, a particle engineering platform that allows for the precise production of uniform drug particles, aimed at improving the safety, efficacy, and performance of various therapies. Liquidia is currently advancing two key product candidates: LIQ861 for the treatment of pulmonary arterial hypertension and LIQ865 for addressing local post-operative pain. In addition to its internal pipeline, Liquidia collaborates with leading pharmaceutical companies to leverage its PRINT technology across multiple therapeutic areas and drug types. The company also offers strategy and commercialization services for rare disease pharmaceutical products, including a generic formulation of treprostinil for pulmonary arterial hypertension. Founded in 2004, Liquidia Technologies continues to focus on transforming patient care through innovative therapeutic solutions.
Xoc utilizes state-of-the-art receptor characterization technology and cutting-edge medicinal chemistry to identify product candidates and develop novel therapies to meet the goal of providing improved safety and efficacy for patients. Xoc manages the clinical and regulatory risk in our development programs by leveraging the extensive pharmacological history of compounds similar to their product candidates.
The name “Xoc” is derived from a term in the Mayan language and is pronounced “shock”.
Aquabyte, Inc. specializes in developing advanced monitoring systems for the aquaculture industry, focusing on enhancing fish farming efficiency through machine learning and computer vision technologies. Founded in 2017 and headquartered in San Francisco with an additional office in Bergen, Norway, Aquabyte's innovative solutions include a smart camera system that facilitates real-time sea lice counting, biomass estimation, appetite detection, and feed optimization. By providing a comprehensive web dashboard for continuous monitoring, Aquabyte enables fish farms to reduce operational costs and minimize environmental impacts, ultimately contributing to a more sustainable and profitable aquaculture sector. The company's commitment to leveraging technology aims to address challenges in food production, making a significant impact on the industry's growth and efficiency.
Personal Genome Diagnostics develops a patient-specific analysis of the cancer genome by using advanced tools and technologies. They were the first to sequence and analyze whole human cancer exomes and subsequently identified many alterations responsible for the development of cancer. They have described the principles underlying the genetic basis of human cancer and have developed novel technologies for non-invasive “liquid biopsy” approaches in cancer. Through PGDx, our founders bring their proprietary methods and expertise to research teams worldwide. The services help oncologists and translational scientists sequence and analyze cancer genomes and identify mutations to characterize aspects of the disease. Their expertise in genome analysis ranges from sample preparation and sequencing to data interpretation and analysis. They specialize in high-throughput next-generation sequencing and proprietary algorithms to identify alterations in complex cancer genomes and have developed novel technologies for non-invasive “liquid biopsy” approaches in cancer. Personal Genome Diagnostics was founded in 2010 and is based in Baltimore, Maryland, United States.
CTI BioPharma Corp. a biopharmaceutical company, develops, acquires, and commercializes oncology products for cancer treatment. Its development portfolio includes Pixantrone, a phase III trial product, for non-Hodgkin's lymphoma; Brostallicin, which is in first-line Phase II study for the treatment of sarcoma; and OPAXIO, a chemotherapeutic agent for the potential treatment of non-small cell lung, ovarian, and other cancers. It has collaboration and licensing arrangements with Novartis International Pharmaceutical, Ltd.; and PG-TXL Company, L.P. The company was founded in 1991 and is headquartered in Seattle, Washington.
Korro Bio Inc. specializes in the development of nucleic acid-based therapeutics aimed at targeting specific sequences in genetic code, with a focus on treating rare diseases. Founded in 2018 and located in Cambridge, Massachusetts, the company utilizes a proprietary platform that enables efficient and selective RNA editing by leveraging natural processes found in multi-cellular organisms. This innovative approach allows Korro Bio to edit messenger RNA and recode specific codons, facilitating targeted modifications in protein structure and function across various tissues.
Pionyr Immunotherapeutics Inc. is a biotechnology company based in San Francisco, California, focused on developing innovative cancer immunotherapies. Established in 2015, the company aims to enhance the body’s antitumor immunity by targeting the tumor microenvironment. Pionyr employs advanced technologies for novel target discovery and antibody generation, which underpin its next-generation immuno-oncology therapeutics. Central to its strategy is the Myeloid Tuning™ approach, designed to specifically modify the cellular composition within the tumor microenvironment, thereby improving the immune system's ability to combat tumors.
Akouos, Inc. is a biotechnology company that specializes in developing gene therapies aimed at restoring and preserving hearing for individuals with hearing loss. The company utilizes a proprietary platform that includes a library of adeno-associated viral vectors and innovative delivery methods. Its lead product candidate, AK-OTOF, targets hearing loss caused by mutations in the OTOF gene. Akouos is committed to addressing various forms of sensorineural hearing loss, which can result from genetic mutations, ototoxic drug exposure, and aging. Founded in 2016 and headquartered in Boston, Massachusetts, Akouos has formed strategic partnerships with organizations such as Massachusetts Eye and Ear and Lonza, Inc. to enhance its research and development efforts.
Catalog Technologies Inc. is a Boston-based company that specializes in a DNA-based platform designed for digital data storage and computation. Founded in 2016, Catalog's innovative platform encodes digital information into DNA, providing a new approach to long-term data archiving. This method not only enhances data storage capacity but also offers a cost-effective solution for managing vast amounts of information. By integrating advanced synthetic biology technologies, Catalog aims to revolutionize the way digital data is archived and processed, making DNA a viable medium for future data storage needs.
Nightstar Therapeutics plc is a clinical-stage gene therapy company based in London, focused on developing innovative one-time treatments for rare inherited retinal diseases. The company’s lead product candidate, NSR-REP1, is currently in phase 3 clinical development for choroideremia, while NSR-RPGR is undergoing phase 2/3 trials for X-linked retinitis pigmentosa. Additionally, Nightstar is developing NSR-BEST1 and NSR-ABCA4, with the latter in preclinical development for Stargardt disease. Founded in 2017, Nightstar Therapeutics aims to address the unmet medical needs of patients suffering from these conditions.
Illumitex Inc. is a manufacturer based in Austin, Texas, specializing in precision LEDs and LED lighting fixtures. Founded in 2005, the company produces a range of lighting products for horticultural, industrial, and architectural applications. Its offerings include grow lights designed for large growers, vertical farms, and greenhouses, as well as lighting solutions for warehouses, offices, cold storage facilities, and food processing plants. Illumitex's innovative designs focus on enhancing functionality through advanced optics technology, delivering uniform and precise light beams. Their products cater to various settings, including indoor gardening, plant research, and commercial landscapes. Illumitex distributes its lighting solutions through retailers and distributors across the United States.
Synlogic, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the discovery and development of synthetic biotic medicines aimed at treating metabolic, inflammatory, and cancer-related diseases. The company’s lead therapeutic program, SYNB1618, is an oral therapy currently in Phase I/IIa clinical trials for the treatment of phenylketonuria. Additionally, Synlogic is developing SYNB1891, an intratumoral synthetic biotic medicine that is undergoing Phase I clinical trials for the treatment of solid tumors and lymphoma. The company is also exploring synthetic biotics for more common conditions, including inflammatory bowel disease and secondary hyperoxaluria. Synlogic has established a collaboration with Ginkgo Bioworks to advance its development of these innovative therapies.
ChromaCode, Inc. is a molecular diagnostics company based in Carlsbad, California, that specializes in developing innovative testing solutions for infectious diseases, cancer, and non-invasive prenatal testing (NIPT) using proprietary technology derived from Caltech. The company enhances the performance of quantitative polymerase chain reaction (qPCR) instruments, achieving a five-fold increase in multiplexing capabilities while maintaining cost-effectiveness. ChromaCode employs advanced bioinformatics techniques and patented mathematical methods to improve signal processing, enabling laboratories to conduct comprehensive testing of multiple targets in a single sample. Additionally, the company offers products such as the HDPCR Tick-Borne Pathogen Panel, which detects various tick-borne pathogens through a multiplex polymerase chain reaction test. Founded in 2012, ChromaCode draws expertise from professionals with backgrounds in leading organizations such as Illumina and Google[x].
Tarveda Therapeutics is focused on developing innovative cancer therapies specifically for solid tumors. The company specializes in miniature drug conjugates, with its lead candidate, PEN-866, targeting activated Heat Shock Protein 90 (HSP90) to deliver a potent topoisomerase 1 inhibitor, SN38, directly to tumor cells. Additionally, Tarveda is advancing another drug conjugate aimed at treating patients with neuroendocrine tumors and small cell lung cancer that express somatostatin receptor 2 (SSTR2). By leveraging its targeted drug delivery platform, Tarveda Therapeutics aims to improve treatment outcomes for patients with difficult-to-treat cancers while reducing potential side effects. Founded in 2011 and based in Watertown, Massachusetts, the company was previously known as Blend Therapeutics until its rebranding in 2016.
Regulus Therapeutics Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery and development of therapies that target microRNAs to address various diseases. Its primary product candidates include RG-012, an anti-miR targeting miR-21, currently in Phase II clinical trials for Alport syndrome, a severe kidney condition, and RGLS4326, an anti-miR aimed at miR-17, which is undergoing Phase Ib clinical trials for autosomal dominant polycystic kidney disease. In addition to these lead candidates, Regulus is cultivating a preclinical pipeline that includes RGLS5579, targeting miR-10b, as well as programs focused on Hepatitis B and Non-Alcoholic Steatohepatitis. Founded in 2007, Regulus Therapeutics is headquartered in San Diego, California.
Immunomedics, Inc. is a clinical-stage biopharmaceutical company based in Morris Plains, New Jersey, that focuses on developing monoclonal antibody-based therapies for cancer treatment. The company's lead product, sacituzumab govitecan, is an antibody-drug conjugate targeting metastatic triple-negative breast cancer, where it is positioned as a third-line treatment in the United States. Additionally, Immunomedics is advancing several other candidates, including IMMU-140 for hematologic malignancies and IMMU-130 for colorectal cancer. The company also explores collaborative clinical efforts with major pharmaceutical partners to enhance the development and application of its products. Founded in 1982, Immunomedics aims to deliver innovative treatments to patients with serious diseases, leveraging its capabilities to drive scientific advancements and operational effectiveness. As of late 2020, it operates as a subsidiary of Gilead Sciences, Inc.
Trillium Therapeutics Inc. is a clinical-stage immuno-oncology company based in Mississauga, Canada, focused on developing therapies for cancer treatment. Its leading program, TTI-621, is a SIRPaFc fusion protein designed to inhibit the CD47 signal, currently undergoing Phase I clinical trials for advanced relapsed or refractory hematologic malignancies, solid tumors, and mycosis fungoides. The company is also advancing TTI-622, another SIRPaFc protein in Phase I trials, and TTI-10001, a small molecule stimulator of interferon genes agonist in the discovery phase aimed at enhancing tumor immunity. Trillium Therapeutics, originally founded in 2004 and previously known as Stem Cell Therapeutics Corp., specializes in the discovery and development of protein therapeutics, including monoclonal antibodies and peptides, with a focus on cancer and other therapeutic areas.
Cleave Therapeutics, Inc. is a biopharmaceutical company based in San Francisco, California, founded in 2010. The company specializes in developing novel small-molecule drugs that target valosin-containing protein and other protein-degradation pathways critical for the survival of cancer cells. By focusing on these mechanisms, Cleave Therapeutics aims to create enzyme inhibitors that can effectively treat cancer and neurodegenerative diseases. Its research efforts are directed toward discovering innovative therapies that may improve patient outcomes in oncology.
AVEO Oncology is a biopharmaceutical company engaged in the development and commercialization of targeted therapies for oncology and other unmet medical needs. The company's lead product, tivozanib, is an oral, once-daily inhibitor of vascular endothelial growth factor receptors, primarily indicated for renal cell carcinoma (RCC). AVEO has completed a Phase III trial (TIVO-3) for tivozanib and is conducting a Phase Ib/II trial combining it with Opdivo, an immune checkpoint inhibitor. Additionally, AVEO is developing Ficlatuzumab, an antibody currently in Phase II trials targeting various cancers, and AV-203, an anti-ErbB3 monoclonal antibody that has completed Phase I trials for esophageal cancer. The company's preclinical pipeline includes AV-380, aimed at cachexia, and AV-353, for pulmonary arterial hypertension. AVEO has established multiple collaboration agreements with various pharmaceutical companies and is involved in clinical trials assessing IMFINZI, an antibody targeting PD-L1. Headquartered in Boston, Massachusetts, AVEO was incorporated in 2001 and has a focus on advancing cancer therapeutics through its proprietary cancer biology platform.
TESARO, Inc. is an oncology-focused biopharmaceutical company established in 2010 and based in Waltham, Massachusetts. The company specializes in the identification, acquisition, development, and commercialization of cancer therapeutics and supportive care products. Its notable offerings include ZEJULA, an oral poly polymerase inhibitor used for the maintenance treatment of recurrent ovarian cancer, and VARUBI, a neurokinin-1 receptor antagonist designed to prevent chemotherapy-induced nausea and vomiting. TESARO is also advancing a range of immunotherapy candidates, such as TSR-042, TSR-022, and TSR-033, all currently in phase I clinical trials. The company has formed various collaboration and licensing agreements with industry partners, including AnaptysBio, Janssen Biotech, and Genentech. In January 2019, TESARO became a subsidiary of GlaxoSmithKline plc, further enhancing its capabilities in cancer treatment innovation.
Synlogic, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the discovery and development of synthetic biotic medicines aimed at treating metabolic, inflammatory, and cancer-related diseases. The company’s lead therapeutic program, SYNB1618, is an oral therapy currently in Phase I/IIa clinical trials for the treatment of phenylketonuria. Additionally, Synlogic is developing SYNB1891, an intratumoral synthetic biotic medicine that is undergoing Phase I clinical trials for the treatment of solid tumors and lymphoma. The company is also exploring synthetic biotics for more common conditions, including inflammatory bowel disease and secondary hyperoxaluria. Synlogic has established a collaboration with Ginkgo Bioworks to advance its development of these innovative therapies.
Tarveda Therapeutics is focused on developing innovative cancer therapies specifically for solid tumors. The company specializes in miniature drug conjugates, with its lead candidate, PEN-866, targeting activated Heat Shock Protein 90 (HSP90) to deliver a potent topoisomerase 1 inhibitor, SN38, directly to tumor cells. Additionally, Tarveda is advancing another drug conjugate aimed at treating patients with neuroendocrine tumors and small cell lung cancer that express somatostatin receptor 2 (SSTR2). By leveraging its targeted drug delivery platform, Tarveda Therapeutics aims to improve treatment outcomes for patients with difficult-to-treat cancers while reducing potential side effects. Founded in 2011 and based in Watertown, Massachusetts, the company was previously known as Blend Therapeutics until its rebranding in 2016.
AVEO Oncology is a biopharmaceutical company engaged in the development and commercialization of targeted therapies for oncology and other unmet medical needs. The company's lead product, tivozanib, is an oral, once-daily inhibitor of vascular endothelial growth factor receptors, primarily indicated for renal cell carcinoma (RCC). AVEO has completed a Phase III trial (TIVO-3) for tivozanib and is conducting a Phase Ib/II trial combining it with Opdivo, an immune checkpoint inhibitor. Additionally, AVEO is developing Ficlatuzumab, an antibody currently in Phase II trials targeting various cancers, and AV-203, an anti-ErbB3 monoclonal antibody that has completed Phase I trials for esophageal cancer. The company's preclinical pipeline includes AV-380, aimed at cachexia, and AV-353, for pulmonary arterial hypertension. AVEO has established multiple collaboration agreements with various pharmaceutical companies and is involved in clinical trials assessing IMFINZI, an antibody targeting PD-L1. Headquartered in Boston, Massachusetts, AVEO was incorporated in 2001 and has a focus on advancing cancer therapeutics through its proprietary cancer biology platform.
Cascadian Therapeutics, a clinical-stage biopharmaceutical company, researches and develops, and sells therapeutic products for the treatment of cancer in the United States.
The company lead clinical-stage product candidate is tucatinib, an orally active and HER2-selective small molecule tyrosine kinase inhibitor, which is in two Phase Ib trials, one in combination with Kadcyla and another in combination with Xeloda and/or Herceptin. It is also developing Checkpoint kinase 1, a protein kinase that is in pre-clinical studies to regulate the cell division cycle, as well as to DNA damage and replication stress.
In addition, the company focuses on the development of novel antibodies and T-cell immunoreceptor with Ig and ITM domains, an inhibitory receptor expressed on T-cells and NK cells that negatively regulate immune response to cancers. It has a license agreement with Array BioPharma Inc. to develop, manufacture and commercialize tucatinib; research collaboration agreement with Sentinel Oncology Ltd. for the discovery of novel Chk1 inhibitors; and collaboration agreement with Adimab LLC for the discovery of novel antibodies against d immunotherapy targets in oncology.
Nightstar Therapeutics plc is a clinical-stage gene therapy company based in London, focused on developing innovative one-time treatments for rare inherited retinal diseases. The company’s lead product candidate, NSR-REP1, is currently in phase 3 clinical development for choroideremia, while NSR-RPGR is undergoing phase 2/3 trials for X-linked retinitis pigmentosa. Additionally, Nightstar is developing NSR-BEST1 and NSR-ABCA4, with the latter in preclinical development for Stargardt disease. Founded in 2017, Nightstar Therapeutics aims to address the unmet medical needs of patients suffering from these conditions.
Personal Genome Diagnostics develops a patient-specific analysis of the cancer genome by using advanced tools and technologies. They were the first to sequence and analyze whole human cancer exomes and subsequently identified many alterations responsible for the development of cancer. They have described the principles underlying the genetic basis of human cancer and have developed novel technologies for non-invasive “liquid biopsy” approaches in cancer. Through PGDx, our founders bring their proprietary methods and expertise to research teams worldwide. The services help oncologists and translational scientists sequence and analyze cancer genomes and identify mutations to characterize aspects of the disease. Their expertise in genome analysis ranges from sample preparation and sequencing to data interpretation and analysis. They specialize in high-throughput next-generation sequencing and proprietary algorithms to identify alterations in complex cancer genomes and have developed novel technologies for non-invasive “liquid biopsy” approaches in cancer. Personal Genome Diagnostics was founded in 2010 and is based in Baltimore, Maryland, United States.
23andMe, Inc. is a consumer genetics company that provides DNA analysis services through home-based saliva collection kits, enabling users to explore their ancestry, inherited traits, and health insights. Founded in 2006 and headquartered in Sunnyvale, California, the company offers various services, including Health + Ancestry and Ancestry + Traits, which provide insights into a person's genetic background and over 30 trait reports. 23andMe aims to help individuals understand the implications of their genetic information while also catering to researchers by offering categorized and searchable data. The company was co-founded by Linda Avey and Anne Wojcicki and has positioned itself as a significant player in the growing biotechnology and healthcare sectors.
Therachon is a global biotechnology company focused on developing medicines for rare, genetic diseases that currently have no available treatments. The company’s lead pipeline candidate, TA-46, is a novel protein therapy in development for achondroplasia, the most common form of short-limbed dwarfism. Therachon is headquartered in Basel, Switzerland, with research labs in Nice, France.
Proteostasis Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for cystic fibrosis and other diseases linked to protein homeostasis. The company’s primary product candidates include PTI-801, a CFTR corrector; PTI-808, a CFTR potentiator; and PTI-428, a CFTR amplifier. Proteostasis employs theratyping to tailor treatment strategies based on individual responses to CFTR modulators, regardless of specific mutations. The company collaborates with the Cystic Fibrosis Foundation and Genentech to advance its research and development efforts. Founded in 2006 and based in Boston, Massachusetts, Proteostasis was previously known as Proteoguard, Inc. and rebranded in 2007. In December 2020, it was acquired by Yumanity Therapeutics in a reverse merger transaction.
Illumitex Inc. is a manufacturer based in Austin, Texas, specializing in precision LEDs and LED lighting fixtures. Founded in 2005, the company produces a range of lighting products for horticultural, industrial, and architectural applications. Its offerings include grow lights designed for large growers, vertical farms, and greenhouses, as well as lighting solutions for warehouses, offices, cold storage facilities, and food processing plants. Illumitex's innovative designs focus on enhancing functionality through advanced optics technology, delivering uniform and precise light beams. Their products cater to various settings, including indoor gardening, plant research, and commercial landscapes. Illumitex distributes its lighting solutions through retailers and distributors across the United States.
Clementia Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company based in Montreal, Canada, focused on developing innovative treatments for patients with ultra-rare bone disorders and other diseases characterized by high unmet medical needs. Founded in 2010, the company specializes in disease-modifying therapies, with its lead product candidate being palovarotene, an oral small molecule. Palovarotene has demonstrated significant potential in preventing abnormal bone formation and fibrosis across various tissues. The candidate is currently undergoing evaluation in the Phase III MOVE trial, targeting conditions such as fibrodysplasia ossificans progressive and multiple osteochondromas, as well as dry eye disease. Clementia's commitment to addressing debilitating health issues highlights its role in advancing treatment options for affected patients.
Mirna Therapeutics, Inc. is a discovery-stage biopharmaceutical company that specializes in developing miRNA-directed therapies for human oncology. With a strong focus on research and a deep understanding of microRNA and cancer biology, Mirna is positioned to advance the emerging field of miRNA-based therapeutics. The company boasts a robust intellectual property portfolio that supports its innovative approach to cancer treatment.
CRISPR Therapeutics AG is a gene editing company dedicated to developing transformative gene-based medicines for serious human diseases using its proprietary CRISPR/Cas9 technology. This revolutionary platform allows for precise modifications to genomic DNA, enabling the company to target a variety of disease areas, including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The lead product candidate, CTX001, is an ex vivo CRISPR gene-edited therapy aimed at treating transfusion-dependent beta thalassemia and severe sickle cell disease by engineering patients' hematopoietic stem cells to produce elevated levels of fetal hemoglobin. Additionally, CRISPR Therapeutics is advancing other therapies, including CTX110, an allogeneic CAR-T therapy for certain malignancies, and additional programs targeting conditions such as multiple myeloma, solid tumors, diabetes, and various genetic disorders. The company collaborates with strategic partners such as Bayer Healthcare, Vertex Pharmaceuticals, and ViaCyte, and is headquartered in Zug, Switzerland.
CRISPR Therapeutics AG is a gene editing company dedicated to developing transformative gene-based medicines for serious human diseases using its proprietary CRISPR/Cas9 technology. This revolutionary platform allows for precise modifications to genomic DNA, enabling the company to target a variety of disease areas, including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The lead product candidate, CTX001, is an ex vivo CRISPR gene-edited therapy aimed at treating transfusion-dependent beta thalassemia and severe sickle cell disease by engineering patients' hematopoietic stem cells to produce elevated levels of fetal hemoglobin. Additionally, CRISPR Therapeutics is advancing other therapies, including CTX110, an allogeneic CAR-T therapy for certain malignancies, and additional programs targeting conditions such as multiple myeloma, solid tumors, diabetes, and various genetic disorders. The company collaborates with strategic partners such as Bayer Healthcare, Vertex Pharmaceuticals, and ViaCyte, and is headquartered in Zug, Switzerland.
PhaseBio Pharmaceuticals is a clinical-stage biopharmaceutical company based in Malvern, Pennsylvania, focused on developing innovative therapies for cardiopulmonary diseases. Its lead product candidate, PB2452, is a reversal agent for the antiplatelet drug ticagrelor and is currently undergoing Phase III clinical trials for patients experiencing uncontrolled bleeding or requiring urgent surgery. The company is also advancing PB1046, a fusion protein aimed at treating pulmonary arterial hypertension, which is in Phase IIb clinical trials. Additionally, PhaseBio is developing PB6440, an oral agent intended for the treatment of resistant hypertension. Founded in 2002, the company leverages proprietary recombinant biopolymers to enhance the stability and efficacy of its drug candidates.
Champions Oncology, Inc. specializes in developing technology solutions and products aimed at personalizing the treatment of cancer. The company employs its Tumorgraft Technology Platform, which involves implanting human tumors in immune-deficient mice, to provide Personalized Oncology Solutions (POS). This platform enables physicians to tailor treatment options based on specific tumor data obtained from drug panels. Additionally, Champions Oncology offers Translational Oncology Solutions to assist pharmaceutical and biotechnology companies in their drug development processes. The company's product offerings include TumorGraft implants and drug panels that evaluate the response of a patient's tumor to various oncology drugs or combinations. Champions Oncology markets its products through online channels, referrals, and a dedicated sales team. Founded by leading experts in cancer research and treatment, the company is headquartered in Hackensack, New Jersey, and was incorporated in 1985.
Surface Oncology was created to advance next-generation approaches to cancer immunotherapy based on proprietary insights about novel immunotherapy targets and emerging areas of cancer immuno-biology. Together with world-leading scientific founders, the Company is advancing multiple preclinical programs that target novel mechanisms shown to play vital roles in tumor immune-evasion. Surface is based in Cambridge, Mass.
Tarveda Therapeutics is focused on developing innovative cancer therapies specifically for solid tumors. The company specializes in miniature drug conjugates, with its lead candidate, PEN-866, targeting activated Heat Shock Protein 90 (HSP90) to deliver a potent topoisomerase 1 inhibitor, SN38, directly to tumor cells. Additionally, Tarveda is advancing another drug conjugate aimed at treating patients with neuroendocrine tumors and small cell lung cancer that express somatostatin receptor 2 (SSTR2). By leveraging its targeted drug delivery platform, Tarveda Therapeutics aims to improve treatment outcomes for patients with difficult-to-treat cancers while reducing potential side effects. Founded in 2011 and based in Watertown, Massachusetts, the company was previously known as Blend Therapeutics until its rebranding in 2016.
Nkarta Therapeutics is a biopharmaceutical company focused on developing engineered natural killer (NK) cell therapies for cancer treatment. Founded in 2015 and headquartered in South San Francisco, California, Nkarta aims to enhance the efficacy and tolerability of cell therapies, addressing both hematologic and solid tumor malignancies. The company's approach utilizes chimeric antigen receptors on NK cells, enabling them to recognize and attack tumor cells more effectively. Nkarta's lead product candidates include NKX101, designed to harness innate NK cell biology for cancer detection and destruction, and NKX019, targeting the CD19 antigen to treat various B cell malignancies. By leveraging its NK expansion platform and proprietary cell engineering technologies, Nkarta seeks to provide a more potent and accessible treatment option, capitalizing on the natural ability of NK cells to identify and eliminate abnormal cells while minimizing side effects typically associated with other therapies.
Sagimet Biosciences is a biotechnology company that focuses on developing novel therapeutics to treat important diseases such as liver disease NASH and specific cancers, with a focus on targeting dysfunctional metabolic pathways. It was founded in 2007 and headquartered in San Mateo, California.
Interleukin Genetics, Inc. is a company that specializes in personalized health through genetic testing. It develops and sells genetic tests aimed at helping individuals improve their health and wellness. The company focuses on two main areas: providing genetic test products directly to consumers and through sales partners, and conducting research and development to create genetic tests in collaboration with partners for medical and dental applications. By offering personalized insights related to chronic diseases and health conditions, Interleukin Genetics aims to empower individuals with the information needed to make informed decisions about their health, including specific dietary and exercise recommendations. This approach aligns with their mission of enhancing preventive health measures and improving overall health outcomes.
Illumitex Inc. is a manufacturer based in Austin, Texas, specializing in precision LEDs and LED lighting fixtures. Founded in 2005, the company produces a range of lighting products for horticultural, industrial, and architectural applications. Its offerings include grow lights designed for large growers, vertical farms, and greenhouses, as well as lighting solutions for warehouses, offices, cold storage facilities, and food processing plants. Illumitex's innovative designs focus on enhancing functionality through advanced optics technology, delivering uniform and precise light beams. Their products cater to various settings, including indoor gardening, plant research, and commercial landscapes. Illumitex distributes its lighting solutions through retailers and distributors across the United States.
Synlogic, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the discovery and development of synthetic biotic medicines aimed at treating metabolic, inflammatory, and cancer-related diseases. The company’s lead therapeutic program, SYNB1618, is an oral therapy currently in Phase I/IIa clinical trials for the treatment of phenylketonuria. Additionally, Synlogic is developing SYNB1891, an intratumoral synthetic biotic medicine that is undergoing Phase I clinical trials for the treatment of solid tumors and lymphoma. The company is also exploring synthetic biotics for more common conditions, including inflammatory bowel disease and secondary hyperoxaluria. Synlogic has established a collaboration with Ginkgo Bioworks to advance its development of these innovative therapies.
Adaptimmune Therapeutics plc is a clinical-stage biopharmaceutical company based in Abingdon, United Kingdom, specializing in innovative cell therapies for cancer treatment, particularly targeting solid tumors. The company utilizes its specific peptide enhanced affinity receptor (SPEAR) T-cell platform to identify and genetically engineer T-cell receptors that enhance the immune response against cancerous cells. Current clinical trials are exploring various therapeutic candidates, including ADP-A2M4 for multiple solid tumor types and ADP-A2AFP for hepatocellular carcinoma. Adaptimmune has formed strategic collaborations with several organizations, including GSK for the development of NY-ESO T-cell therapy and Noile-Immune Biotech Inc. for combining SPEAR T-cells with PRIME technology. Founded in 2008, Adaptimmune is committed to advancing T-cell therapies to improve patient outcomes in oncology and beyond.
Synlogic, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the discovery and development of synthetic biotic medicines aimed at treating metabolic, inflammatory, and cancer-related diseases. The company’s lead therapeutic program, SYNB1618, is an oral therapy currently in Phase I/IIa clinical trials for the treatment of phenylketonuria. Additionally, Synlogic is developing SYNB1891, an intratumoral synthetic biotic medicine that is undergoing Phase I clinical trials for the treatment of solid tumors and lymphoma. The company is also exploring synthetic biotics for more common conditions, including inflammatory bowel disease and secondary hyperoxaluria. Synlogic has established a collaboration with Ginkgo Bioworks to advance its development of these innovative therapies.